

**HIV Pharmacy Association Study Day**  
Wednesday 8<sup>th</sup> November 2017

**Topic for the day: Hepatitis C and Co-morbidities**

**Venue: Hotel Pullman, 100-110 Euston Road, London NW1 2AJ**

This study day will be streamed live using WebEx. The link will be sent to HIVPA members before the day.

**NB:** Please note HIV Pharmacy Association cannot be held responsible for individual issues that may be experienced as part of the WebEx web streaming function, such issues may be related to individual browsers.

HIV Pharmacy Association are dedicated to ensuring professional education and training opportunities for members and delegates but are not responsible for the content of presentations and other information supplied by individual speakers and/or organisations.

**Study Day Programme**

**09.00-09.20** – Arrival and registration

**09:20 – 09:30** – Chair introduction

**09.30- 10.30 – Session 1:** Diabetes, Cardiology and HIV symposium – Dr Graeme Moyle, Chelsea and Westminster NHS Foundation Trust

- Learn about the increased risk of diabetes and cardiovascular conditions in an HIV-infected individual and the risk factors that play a part in this;
- Discuss diabetes testing strategies among HIV-infected patients;
- Explain cardiovascular and diabetes management strategies, including lifestyle changes and medications, for use in HIV clinical care;
- Explore the drug interactions between cardiovascular and antidiabetic agents and antiretroviral medications and how to manage these in a clinical setting;
- Discuss the macrovascular and microvascular complications of diabetes in HIV-infected patients

This meeting is supported by Gilead Sciences, Merck Sharp and Dohme, Janssen, ViiV Healthcare UK, Abbvie and Mylan and who have provided part funding

**10:30- 11:00- Industry Update:** Paraskevi Skamnioti, MSD

**11.00-11:15 – Coffee break**

**11:15- 12:15 – Session 2:** HIV and the Kidney - Dr Jeremy Levy, Imperial College NHS Trust

Key objectives:

- Describe the clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection – acute, chronic, end stage renal disease;
- Describe the management of kidney disease in HIV infected individuals;
- Explain the impact of ART on renal function in HIV infected individuals;
- Explore the complications involving HIV infected patients who are undergoing or have undergone renal transplantation and the drug interactions to manage;
- Review of one or two case studies.

**12.15-13:15 – Session 3:** Dr Lucy Garvey, Imperial College NHS Trust

Chronic hepatitis B

Key objectives:

- Differentiate between the various stages of hepatitis B;
- Explain the monitoring requirements and antiviral treatment agents available;
- Learn about the national BASHH and NICE chronic hepatitis B diagnosis and management guidelines;
- Explain the differences in treatment guidelines comparing NICE with EASL and AASLD;
- Describe the current and future challenges faced by healthcare professionals in the management of chronic hepatitis B.

**13:15- 14:15 – Lunch**

**14:15- 14:45 – Industry Update:** Abbvie

**14.45-15:45 – Session 4:** Dr Ruth Byrne, Kings College London

Hepatitis C – the condition

This meeting is supported by Gilead Sciences, Merck Sharp and Dohme, Janssen, ViiV Healthcare UK, Abbvie and Mylan and who have provided part funding

Key objectives:

- Review the epidemiology and pathophysiology of hepatitis C virus (HCV);
- Describe the risk factors for HCV and diagnosis of HCV;
- Identify goals of HCV therapy;
- Explain the mechanisms of HCV resistance;
- Eliminating hepatitis C as a major public health threat – explain the challenges ahead.

**15.45- 16:00 – Coffee break**

**16:00- 1700 – Session 5:** Adele Torkington, North Manchester General Hospital

Hepatitis C - Role of the specialist HIV and Hepatitis C pharmacist

Key Objectives:

- Identify patient-specific factors relevant to drug therapy selection and associated modifications;
- List HCV treatment options and associated monitoring parameters;
- Explain the ways in which HCV infection management with the new direct-acting antiviral drugs differs from management with the older interferon-ribavirin combination;
- Discuss pharmacist interventions to optimise HCV management success;
- Explain challenges facing pharmacists – including the future of HCV therapy.

**17:00** Close and evaluation

**NOTE:** This Study Day is free to our members. If you are not a member then a payment of £10.00 is required for our February Study Day and for April, September and November Study Days the charge is £15.00 is required at the time of booking.

Please check our website [www.hivpa.org](http://www.hivpa.org) or contact [hivpaoffice@gmail.com](mailto:hivpaoffice@gmail.com) for details of payment methods.

This meeting is supported by Gilead Sciences, Merck Sharp and Dohme, Janssen, ViiV Healthcare UK, Abbvie and Mylan and who have provided part funding

Rev1/V1/draft June 2016/md